Brief: WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta
06/07/2020 12:27
July 6 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* WEP CLINICAL PARTNERS WITH NABRIVA THERAPEUTICS FOR THE
NAMED
PATIENT SUPPLY OF XENLETA® (LEFAMULIN)
Source text for Eikon: ID:nBw7QsMqca
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update